VYEPTI Drug Profile

✉ Email this page to a colleague

Summary for Tradename: VYEPTI

High Confidence Patents:	0
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for VYEPTI

Recent Clinical Trials for VYEPTI

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Chicago Headache Center & Research Institute	Phase 4
H. Lundbeck A/S	Phase 4
H. Lundbeck A/S	Phase 3

See all VYEPTI clinical trials

Pharmacology for VYEPTI

Mechanism of Action	Calcitonin Gene-related Peptide Antagonists
Established Pharmacologic Class	Calcitonin Gene-related Peptide Antagonist

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for VYEPTI Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for VYEPTI Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for VYEPTI Derived from Patent Text Search

No patents found based on company disclosures

VYEPTI Market Dynamics, Financial Trajectory, Patent Protection and Competitive Outlook

Last updated: September 8, 2026

VYEPTI, Lundbeck’s eptinezumab-jjmr, has developed into a material growth product in the migraine market. Global sales increased from approximately DKK 1.1 billion in 2022 to about DKK 2.4 billion in 2024, driven by wider chronic-migraine use, commercial expansion in the United States, and demand for a quarterly preventive treatment administered by health-care professionals. Its principal commercial constraints are intravenous administration, payer controls, infusion-site access, and competition from lower-friction injectable and oral CGRP therapies. [1]

The product benefits from biologic regulatory exclusivity through February 2032 in the United States, while patent protection is expected to extend beyond that period based on eptinezumab composition, formulation, and use-related patent families. No VYEPTI biosimilar has been approved in the United States, and no major publicly reported Paragraph IV or BPCIA challenge had materially altered the product’s U.S. exclusivity position through 2024.

What is VYEPTI and how does it compete in migraine prevention?

VYEPTI is an intravenous monoclonal antibody targeting calcitonin gene-related peptide, or CGRP. It is approved for the preventive treatment of migraine in adults. The standard approved dose is 100 mg every three months, with 300 mg available for patients requiring greater efficacy. [2]

Product attribute	VYEPTI
Active ingredient	Eptinezumab-jjmr
Sponsor	Lundbeck
U.S. approval	February 21, 2020
Initial indication	Preventive treatment of migraine in adults
Chronic migraine expansion	2021
Administration	Intravenous infusion
Dosing interval	Every three months
Approved doses	100 mg and 300 mg
Drug class	Anti-CGRP monoclonal antibody
FDA pathway	Biologics license application
Primary commercial market	United States

VYEPTI’s main product differentiation is delivery under clinical supervision every 12 weeks. Eptinezumab reaches systemic exposure immediately after infusion, and clinical studies reported preventive effects beginning early after administration. The same delivery model creates a barrier: patients must schedule an infusion, obtain access to an infusion center, and often navigate medical-benefit reimbursement rather than pharmacy-benefit reimbursement.

How has VYEPTI revenue changed since launch?

VYEPTI sales have followed a steep post-launch growth curve. Lundbeck’s reported product revenue, rounded to the nearest DKK 0.1 billion, was approximately:

Fiscal year	VYEPTI revenue	Approximate annual growth
2020	DKK 0.2 billion	Launch year
2021	DKK 0.6 billion	More than 150%
2022	DKK 1.1 billion	About 80%
2023	DKK 1.8 billion	About 60%
2024	DKK 2.4 billion	About 35%

Source: Lundbeck annual reports and company financial disclosures. [1]

The trajectory reflects three commercial phases:

Launch and access building, 2020-2021. Lundbeck established infusion-center coverage, specialty-pharmacy distribution, and reimbursement pathways while operating during the COVID-19 disruption to elective and office-based care.
Indication expansion and adoption, 2022-2023. Use broadened as physicians treated patients with chronic migraine and as awareness of CGRP-targeted prevention increased.
Scale and mix optimization, 2024 onward. Growth increasingly depends on retention, dose selection, commercial contracting, and penetration of patients who are dissatisfied with oral preventives or self-administered injections.

VYEPTI remains smaller than Lundbeck’s mature products, but its growth rate has made it one of the company’s key newer assets. The product’s sales trajectory also reduces Lundbeck’s dependence on older products facing generic erosion.

What is the commercial outlook for VYEPTI?

The addressable market is large. Migraine affects roughly 39 million people in the United States, although only a fraction receive preventive pharmacotherapy and an even smaller fraction receive biologic CGRP treatment. [3]

VYEPTI’s most attractive commercial segments are:

Patients with frequent or chronic migraine.
Patients who have failed or discontinued oral preventive medicines.
Patients who prefer infrequent dosing.
Patients who have difficulty with self-injection.
Patients already receiving office-based migraine care.
Patients seeking rapid onset or predictable administration.

The principal growth levers are:

Growth lever	Commercial effect
Higher chronic-migraine penetration	Expands use beyond episodic migraine
300 mg utilization	Increases revenue per treated patient
Better medical-benefit coverage	Reduces pharmacy-benefit restrictions
Infusion-center partnerships	Improves treatment availability
Switching from oral preventives	Supports new patient acquisition
International expansion	Extends growth beyond the U.S.

The main risks are payer step therapy, prior authorization, competition from self-injectable antibodies, and oral CGRP drugs. A patient may prefer a quarterly infusion, but a payer may favor a product dispensed through the pharmacy benefit or a lower-cost generic preventive.

How does VYEPTI compare with Aimovig, Ajovy, Emgality and QULIPTA?

VYEPTI competes in a crowded CGRP market that includes three other monoclonal antibodies and oral gepants.

Product	Molecule	Administration	Typical interval	Principal competitive strength
VYEPTI	Eptinezumab	IV infusion	Quarterly	Rapid systemic exposure and clinician-administered dosing
Aimovig	Erenumab	Subcutaneous injection	Monthly or quarterly, depending on product	First-to-market positioning
Ajovy	Fremanezumab	Subcutaneous injection	Monthly or quarterly	Flexible dosing
Emgality	Galcanezumab	Subcutaneous injection	Monthly	Broad migraine commercial presence
QULIPTA	Atogepant	Oral tablet	Daily	No injection or infusion
Nurtec ODT	Rimegepant	Oral tablet	Every other day for prevention	Preventive and acute-treatment utility
Botox	OnabotulinumtoxinA	Office injections	Approximately every 12 weeks	Established chronic-migraine position

VYEPTI’s most direct biologic competitors are Aimovig, Ajovy, and Emgality. QULIPTA and Nurtec create a different threat because they eliminate infusion requirements. Botox remains important in chronic migraine, particularly among patients already treated in neurology or headache clinics.

VYEPTI has a stronger clinical-office orientation than the self-injected antibodies. That can support adherence and physician control, but it also creates exposure to infusion capacity, site-of-care policies, and administration costs.

What patents protect VYEPTI?

VYEPTI is protected by a layered biologic patent estate rather than a single patent. The relevant categories include:

Eptinezumab and related anti-CGRP antibody composition claims.
Antibody sequence and binding claims.
Pharmaceutical formulation claims.
Stabilized liquid or concentrated compositions.
Methods of treating episodic migraine.
Methods of treating chronic migraine.
Dosing and administration regimens.
Manufacturing and cell-culture processes.

The FDA does not provide an Orange Book-style patent table for biologics. VYEPTI is licensed under a biologics license application and is therefore principally tracked through the Purple Book and the BPCIA framework rather than the small-molecule Orange Book framework. [4]

The commercial importance of the estate is concentrated in three areas:

Protection category	Relevance to generic or biosimilar entry
Composition patents	Can block products using the same antibody or substantially identical molecule
Formulation patents	Can constrain commercially practical liquid or concentrated presentations
Method-of-use patents	Can create infringement exposure for labeled migraine-prevention use
Manufacturing patents	May raise development costs but are less likely to block all noninfringing production routes
Regulatory exclusivity	Prevents biosimilar approval for the statutory period even if patent issues are resolved

Publicly available patent records identify multiple U.S. patent families associated with eptinezumab and its use. Expiration dates vary by patent, terminal disclaimers, patent-term adjustment, and continuation practice. The commercially relevant protection is expected to extend beyond the February 2032 U.S. biologic data-exclusivity date, with some use and formulation claims potentially reaching the mid-2030s.

When does VYEPTI lose U.S. exclusivity?

VYEPTI’s U.S. biologic reference-product exclusivity began with FDA approval on February 21, 2020.

Under the BPCIA, a reference biologic receives 12 years of data exclusivity. On that basis, the statutory reference-product exclusivity period runs to approximately February 21, 2032. [5]

Exclusivity layer	Expected timing
FDA approval	February 21, 2020
Four-year biosimilar submission bar	Approximately February 21, 2024
Twelve-year reference-product exclusivity	Approximately February 21, 2032
Patent-based protection	Potentially beyond 2032, including mid-2030s claims
Earliest practical biosimilar launch	Depends on patent resolution, settlement, and FDA approval

The 2021 chronic-migraine label expansion did not reset the 12-year biologic exclusivity period. A new indication can create additional method-of-use patents, but it does not create a second reference-product exclusivity period for the same biologic.

Are there Paragraph IV challenges or biosimilar lawsuits involving VYEPTI?

Paragraph IV litigation is a Hatch-Waxman mechanism associated mainly with small-molecule drugs. VYEPTI is a biologic, so a biosimilar entrant would generally proceed under the BPCIA rather than filing a traditional Paragraph IV certification against an Orange Book listing.

Through 2024, there was no publicly reported FDA-approved VYEPTI biosimilar and no widely disclosed BPCIA litigation that had produced a market-entry settlement or launch date. The absence of a public challenge does not eliminate future risk. Biosimilar developers can begin development before a commercial launch becomes visible, and disputes may emerge through patent-list exchanges, declaratory actions, or infringement litigation.

Potential future challengers would most likely include:

Large biosimilar manufacturers with monoclonal-antibody capability.
Global contract development and manufacturing organizations.
Companies with established U.S. specialty-pharmacy and infusion channels.
Originator companies seeking to license or co-commercialize a follow-on product.

What FDA and regulatory factors affect VYEPTI’s market position?

The FDA approved VYEPTI for migraine prevention based on clinical evidence in episodic and chronic migraine populations. The product’s regulatory profile supports use across a broad preventive population, but its administration route affects both prescribing and reimbursement. [2]

Regulatory and access factors include:

IV administration in a health-care setting.
Medical-benefit billing in some payer arrangements.
Prior authorization and step-edit requirements.
Site-of-care restrictions.
Need for trained infusion personnel.
Potential wastage or scheduling inefficiency for single-patient doses.
Absence of an oral or self-administered presentation.

The product is not a biosimilar, and it is not subject to the generic substitution rules that apply to conventional small molecules. Interchangeability standards for a future biosimilar would be determined under the BPCIA and FDA guidance, not through automatic Orange Book substitution.

How strong is the VYEPTI patent estate?

VYEPTI’s patent estate is commercially meaningful but not unassailable. Its strongest elements are likely the core antibody and use-related protections. Formulation and manufacturing patents can complicate entry, but they often permit alternative development paths.

Strengths

Biologic data exclusivity extends into 2032.
Multiple patent categories create layered entry barriers.
A biologic is more difficult to reproduce than a small molecule.
Clinical comparability requirements increase biosimilar development cost.
Migraine-prevention use provides a substantial commercial indication.

Vulnerabilities

Core composition claims may expire before the full continuation estate.
Biosimilar manufacturers can design around formulation and manufacturing claims.
Method-of-use claims may be narrower than product claims.
Infusion administration creates a commercial opportunity for lower-cost self-injected or oral competitors.
Payer pressure can reduce the economic value of late-stage patent protection.

Overall, VYEPTI has a stronger near-term exclusivity position than a conventional small-molecule product approaching loss of exclusivity. Its longer-term risk is more likely to come from market substitution and payer economics before complete legal erosion.

What generic launch risks exist for VYEPTI?

A conventional generic launch is not the principal threat. The relevant threat is biosimilar or interchangeable-biologic entry after regulatory and patent barriers are cleared.

A realistic U.S. entry sequence would include:

Biosimilar development and analytical comparability work.
FDA submission after the statutory submission bar.
BPCIA patent-exchange procedures or related litigation.
Resolution through litigation, license, or settlement.
FDA approval and commercial contracting.
Payer-driven substitution or formulary placement.

The earliest broad biosimilar pressure is more likely after 2032, while commercial launch could occur later if key patents survive or if Lundbeck reaches a delayed-entry settlement.

What licensing deals and corporate transactions affect VYEPTI?

VYEPTI originated with Alder BioPharmaceuticals. Lundbeck acquired Alder in 2019 for approximately $1.95 billion, including assumed debt, gaining VYEPTI and Alder’s CGRP platform. [6]

The acquisition gave Lundbeck:

A late-stage migraine biologic.
Commercial rights and development control for VYEPTI.
Entry into the expanding CGRP preventive market.
A product capable of offsetting erosion in older Lundbeck brands.

The transaction also transferred development and launch risk to Lundbeck. VYEPTI’s sales growth has supported the strategic rationale, but the asset’s return depends on maintaining growth against increasingly competitive CGRP pricing and delivery formats.

What revenue exposure does VYEPTI create for Lundbeck?

At approximately DKK 2.4 billion in 2024 sales, VYEPTI represented a meaningful portion of Lundbeck’s revenue growth but remained below the company’s largest products. Its financial importance has three dimensions:

It is one of Lundbeck’s principal growth assets.
It diversifies revenue away from mature antidepressant and neurological products.
It creates long-duration exposure to migraine treatment, provided Lundbeck maintains reimbursement and market share.

The main downside risk is a slowdown in new-patient starts as the CGRP class matures. The main upside risk is continued conversion from oral preventives and increased use of 300 mg dosing in chronic or difficult-to-treat migraine.

Key Takeaways

VYEPTI sales rose from roughly DKK 1.1 billion in 2022 to about DKK 2.4 billion in 2024.
Lundbeck acquired VYEPTI through its approximately $1.95 billion acquisition of Alder BioPharmaceuticals.
The product competes with Aimovig, Ajovy, Emgality, QULIPTA, Nurtec ODT, and Botox.
Its commercial differentiation is quarterly IV administration and rapid systemic exposure.
Its main weakness is the operational burden of infusion compared with oral and self-injected alternatives.
U.S. biologic data exclusivity runs approximately through February 2032.
Patent protection is expected to extend beyond 2032 through composition, formulation, method-of-use, and manufacturing claims.
VYEPTI is governed by the BPCIA and Purple Book framework, not the traditional Orange Book Paragraph IV system.
No VYEPTI biosimilar had been approved in the United States through 2024.
The most significant medium-term risks are payer restrictions, class competition, and site-of-care economics rather than immediate generic substitution.

FAQs

Is VYEPTI a biologic or a small-molecule drug?

VYEPTI is a biologic monoclonal antibody. Its active ingredient is eptinezumab-jjmr, an anti-CGRP antibody.

How often is VYEPTI administered?

VYEPTI is administered by intravenous infusion once every three months. The approved doses are 100 mg and 300 mg.

Does VYEPTI have an Orange Book listing?

VYEPTI is a biologic licensed under a BLA. Its regulatory and patent framework is primarily associated with the FDA Purple Book and BPCIA, not the conventional Orange Book system used for small-molecule drugs.

Could a VYEPTI biosimilar launch before 2032?

A biosimilar application could be submitted after the statutory submission bar, but FDA approval and commercial launch would still depend on patent resolution and the end of the 12-year reference-product exclusivity period.

Is VYEPTI more commercially differentiated than self-injected CGRP antibodies?

VYEPTI has a distinct quarterly, clinician-administered delivery model and rapid systemic exposure. Self-injected antibodies have lower administration burden, which can give them an advantage in payer and patient preference.

References

H. Lundbeck A/S. (2023). Annual report 2023. Copenhagen, Denmark: Author.
U.S. Food and Drug Administration. (2024). VYEPTI (eptinezumab-jjmr) prescribing information. Silver Spring, MD: Author.
Lipton, R. B., Bigal, M. E., Diamond, M., Freitag, F., Reed, M. L., & Stewart, W. F. (2007). Migraine prevalence, disease burden, and the need for preventive therapy. Neurology, 68(5), 343-349.
U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. Silver Spring, MD: Author.
Biologics Price Competition and Innovation Act of 2009, Pub. L. No. 111-148, §§ 7001-7002, 124 Stat. 119 (2010).
Lundbeck A/S. (2019). Lundbeck completes acquisition of Alder BioPharmaceuticals. Copenhagen, Denmark: Author.

More… ↓

⤷ Start Trial